which can shorten treatment duration and cost, include hypofractionated WBI (HFRT), accelerated partial breast irradiation (APBI) and endocrine therapy-alone (ET-alone). We sought to evaluate the proportion of patients that would be eligible for these alternatives using the National Cancer Database (NCDB). Methods: Using the 2016 dataset, 1,895,245 patients with Stage I-III breast cancer were identified. Men, patients age <40 years, unknown pathologic stage, and unknown estrogen receptor status were excluded. A total of 1,157,788 patients were eligible for this analysis, of which 819,210 patients were pN0. Eligibility for HFRT, APBI and ET-alone was defined using eligibility criteria from large clinical trials as well as consensus guidelines. Results: Of the patients with pN0 breast cancer, 20.6% and 37.0% were eligible for endocrine therapy (ET)-alone based on the CALGB 9343 and PRIME-II trials, respectively. In terms of HFRT, 72.5% and 50.4%were eligible based on the IMPORT LOW trial and ASTRO HFRT guidelines, respectively. Based on the IMPORT LOW trial, the GEC-ESTRO trial, ASTRO APBI guidelines, ABS APBI guidelines, and GEC-ESTRO APBI guidelines, 72.5%, 86.1%, 39.0%, 72.5%, 45.7%, respectively, were eligible for APBI. Of the women eligible for HFRT per ASTRO guidelines (nZ413,074), approximately 90% were eligible for APBI and 50% were eligible for ET-alone. Of the women eligible for APBI, approximately 50% were eligible for ET-alone and 100% were eligible for HFRT.
Purpose: To assess the impact of axillary ultrasound (AUS) on treatment of breast cancer. The pre-operative (AUS) with or without ultrasound guided biopsy is being increasingly used in the pre-operative workup of breast cancer. We sought to assess the impact of AUS on treatment of breast cancer. Methods: Retrospective chart review of 162 consecutive patients newly diagnosed with breast cancer between 2010 and 2016. All women underwent axillary ultrasonography followed by percutaneous core biopsy of lymph nodes if the AUS results were suspicious for cancer involvement. Results: All except 8 patients were T1-T2. 8 patients were Tis clinical stage group, 75 were IA, 1 was IB, 44 were IIA, 20 were IIB, 11 were IIIA, 2 were IIIB, and 1 was IIIC. 65 (40%) of women underwent core biopsies of axillary lymph nodes before surgery. 42 (65%) of these, had a positive biopsy. Compared to patients with negative AUS and/or negative axillary biopsy, AUS lymph node biopsy positive was significantly associated with: receipt of mastectomy versus lumpectomy (p-value < 0.0035); receipt of neoadjuvant chemotherapy versus adjuvant or no chemotherapy (p-value < 0.0001); planned axillary lymph node dissection versus sentinel lymph node biopsy (p-value < 0.0001); receipt of breast MRI (p-value < 0.0001); lymph node radiation versus no lymph node radiation (p-value < 0.0001); and family history of breast cancer (p-value < 0.0342). Conclusions: Our findings show that patients with a diagnosis of breast cancer and positive axillary lymph node biopsy with AUS were more likely to receive mastectomy, planned axillary lymph node dissection, neoadjuvant chemotherapy, breast MRI, adjuvant radiation and adjuvant axillary lymph nodal radiation. Previous studies of this subtype demonstrated a higher propensity for lymph node metastases compared with invasive ductal carcinoma. Due to this lymphotropic nature, patients with IMPC were once thought to experience worse survival outcomes compared to invasive ductal carcinoma. Our group previously performed analyses of IMPC patients using the Surveillance, Epidemiology, and End Results database and found survival outcomes comparable to invasive ductal carcinoma. In this study, we aim to validate those findings using the National Cancer Data Base (NCDB). Materials/Methods: The NCDB was used to retrieve patients with biopsyproven IMPC diagnosed from 2004-2012. Cox multivariate regression was used to determine prognostic factors. Results: Of 1,096,468 patients with invasive breast cancer, 1,818 (0.2%) had IMPC and sufficient follow-up. At a median follow-up of 4 years, 5yr overall survival (OS) was 87.5% (95% Confidence Interval 85.6-89.4%). At presentation, 55.2% of patients had nodal involvement. Patients with 4+ positive lymph nodes had worse OS (hazard ratio [HR], 3.78; P<0.001) than patients with node-negative disease. However, those with 1-3 positive nodes had an OS similar to patients with node-negative disease. Other poor prognostic factors included comorbidity score >1 (HR 5.56; P<0.001) and distant metastasis (HR 5.37; P<0.001). Factors associated with a good prognosis included age <50 (HR 0.54; PZ0.002), receipt of external beam radiotherapy (HR 0.53; P<0.001), Hispanic/Asian ethnicity (HR 0.48; PZ0.011), and ER-positivity (HR 0.48; P<0.001). Conclusions: Although IMPC has a high propensity for lymph node metastasis, OS is comparable to the historical OS of invasive ductal carcinoma. The receipt of radiotherapy was associated with a better prognosis on multivariate analysis. This is the largest study of IMPC to date, and these findings validate our previous population-based analysis in a more contemporary patient population.
(P009) Assessment of Lumpectomy Cavity Radiotherapy Boost Volume With Repeat CT Simulation Aman Saini, BBA, 1 Steven Sckolnik, MD, 2 and Anushka Patel, MD 2 ; 1 Midwestern University, 2 Arizona Center for Cancer Care Purpose: Lumpectomy cavity (LC) radiotherapy boost after breast conserving surgery and whole breast irradiation (WBRT) reduces local cancer recurrence. Radiotherapy boost correlates with increased rates of fibrosis and may have worse cosmetic outcomes. LC volumes and subsequent boost volumes may decrease with increasing time from surgery. This study evaluates the timing of CT simulation and radiotherapy technique for cavity directed radiotherapy boost. We seek to determine if repeat CT simulation results in smaller boost volumes which may minimize treatment related toxicity and maximize local tumor control. Patients & Methods: A retrospective chart review examined 47 consecutive patients receiving WBRT with LC boost after breast conserving surgery. All patients underwent CT simulation prior to WBRT and repeat CT simulation prior to LC boost. The WBRT prescription dose ranged from 4240-5040cGy and boost from 1000-1600cGy. The LC was contoured on the pre and post CT images and delineated by surgical clips and seroma cavity. Results: 40 of 47 patients reviewed were found to have decreased LC volumes. The mean initial and repeat LC volumes were 71.1cc and 42.6cc 
